Where the Money Goes: Amorphous Dispersion Manufacturing

Manufacturing technology choices can influence a drug product’s costs throughout development and commercial supply. This case study compares the modeled economics of spray drying and KinetiSol™ for a commercially approved oral small molecule. At commercial scale, the model projects annual cost of goods falling from $20 million to $12 million, alongside elimination of organic solvents and three processing steps. It also projects eight months earlier market entry and $50 million to $100 million in lifetime operating savings. Readers will see how evaluating KinetiSol early can simplify manufacturing, reduce costs and strengthen long-term commercial value before a formulation process is established.

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.


  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the phone number you would like to be contacted at.

  • Please enter the e-mail address you would like to be contacted at.

  • By submitting this form, you consent to Pharmaceutical Outsourcing storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.